Medicamen Biotech Ltd Share Price Today - Medicamen Biotech Ltd Stock Price Live NSE/BSE

Medicamen Biotech Ltd

NSE: MEDICAMEQ BSE: 531146

₹223.30

(-6.49%)

Fri, 03 Apr 2026, 00:46 pm

MTF 5xInvest in Medicamen Biotech Ltd with 5x Leverage Buy with MTF

Market Cap3.05B

PE Ratio31.60

Dividend0.42

Health Technology

Pharmaceuticals: Major

24.5K

Medicamen Biotech Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
313.10
Net Profit
6.56
P/B
2.87
Sector P/E
31.31
P/E
86.17
EV/EBITDA
31.09
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.96
ROCE (Industry)
16.65
RONW (Industry)
14.66
ROE
3.12
ROCE
5.56
Debt/Equity
0.15
EPS (TTM)
6.94
Dividend Yield
0.41
Book Value
203.06
Interest Cover
3.66

Analysis

all

Pros

Medicamen Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Medicamen Biotech is profitable, therefore cash runway is not a concern.
Medicamen Biotech is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (82.1%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 20x debt.

Cons

Medicamen Biotech is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of Medicamen Biotech's dividends as it is not paying a notable one for India.
Medicamen Biotech is not paying a notable dividend for India, therefore no need to check if the payments are stable.
Medicamen Biotech's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Medicamen Biotech's dividend is below the markets top 25% of dividend payers in India (3.08%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	40.46	40.46	40.46	43.16	42.99
FII	0.02	0.06	0.00	0.12	0.05
DII	0.44	0.59	0.64	0.69	0.87
Public	59.03	58.85	58.84	55.98	56.04
Government	0.05	0.05	0.05	0.06	0.06

Technical Analysis

RSI

26.90

MACD

-23.15

50 DMA

308.68

200 DMA

356.43

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	435.60	342.80	283.05	250	190.25	157.20	64.40
Fibonacci	342.80	307.35	285.45	250	214.55	192.65	157.20
Camarilla	248.82	240.31	231.81	250	214.79	206.29	197.78

Pivots Level: Classic

+185.60

435.60

+92.80

342.80

+33.05

283.05

250

Pivot Point

LTP: 228.97

-59.75

190.25

-92.80

157.20

-185.60

64.40

Moving Average

SMAEMA

Period

Value

10-EMA
243.74
20-EMA
261.41
30-EMA
276.25
50-EMA
298.15
100-EMA
327.21
200-EMA
359.11

Announcement Date	Purpose	Action	Ex Date
13 Feb 2026	board-meetings	Quarterly Results
14 Nov 2025	board-meetings	Quarterly Results
19 Aug 2025	dividend	Final Dividend - Rs. - 1	19 Sept 2025
12 Aug 2025	agm
30 May 2025	dividend	₹1.00 Dividend /Share	19 Sept 2025
26 Feb 2025	egm
10 Sept 2024	agm
19 Aug 2024	dividend	Annual General Meeting/Dividend - Re 1 Per Share	20 Sept 2024
29 May 2024	dividend	₹1.00 Dividend /Share	19 Sept 2024
20 Aug 2023	dividend	Annual General Meeting/Dividend - Re 1 Per Share	21 Sept 2023

Medicamen Biotech Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd

Medicamen Biotech Ltd About

Medicamen Biotech is engaged in Generic Finished Dosage Forms, Oncology Formulations and Research & Development services to cater to the needs of the Global Pharmaceuticals Industry.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1993

Headquarters

CEO

Rahul Bishnoi

Employees

Contact

Website

http://www.medicamen.com

cs@medicamen.com

Phone

91-11-47589500

Location

1506 Chiranjiv Tower 43, Nehru Place, New Delhi, New Delhi, 110019

Year	History
2019	FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant.
2020	Global API Facility started Dahej API Plant.
2021	Operations started Haridwar formulation Unit II(FDF).
2023	Medicamen Biotech Gains On Successful Anda Filing For Bortezomib Injections.
2024	Medicamen Biotech's Bhiwadi Manufacturing Facility Secures EU GMP Approval from Greece. Medicamen Biotech's Sterile injectable Facility Received USFDA Approval.

Client Name	Order Side	QTY	Avg Price	Date
GROWEL REMEDIES LIMITED	Sell	200000	421.86	22 Mar 2024
SHIVALIK RASAYAN LIMITED	Buy	200000	421.86	22 Mar 2024
JMP SECURITIES PVT LTD	Sell	53811	252.11	16 Nov 2016
JMP SECURITIES PVT LTD	Buy	55011	250.96	16 Nov 2016
MEDICAMEN CANADA INC	Sell	140000	44.08	01 Mar 2016
BP FINTRADE PRIVATE LIMITED	Sell	52306	76.83	07 Jan 2016
VISIONSTAR	Buy	50000	76.51	07 Jan 2016
BP FINTRADE PRIVATE LIMITED	Buy	22012	77.3	07 Jan 2016
RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED	Buy	48498	35.7	16 Nov 2015
GEOMETRIC SECURITIES & ADVISORY P LTD	Sell	51190	35.7	16 Nov 2015

Medicamen Biotech Ltd News

Medicamen Biotech receives NSE cautionary letter

Medicamen Biotech Limited disclosed receiving a cautionary letter from NSE on January 27, 2026, regarding observations in its Secretarial Compliance Report for FY2025, with no financial impact.

21 Feb 2026

stocks

Medicamen Biotech Q3 FY26 Results Show Mixed Performance

Medicamen Biotech reported Q3 FY26 standalone net profit of ₹259.44 lakhs vs ₹252.27 lakhs YoY, with revenue at ₹4,349.07 lakhs. Board approved committee reconstitution following director tenure completion.

13 Feb 2026

co actions results

Medicamen Biotech Gets EU Approval for Paracetamol

Medicamen Biotech receives European Union approval for registration of paracetamol product from Denmark in partnership with XGX Pharma, marking regulatory milestone for the pharmaceutical company.

08 Jan 2026

stocks

Medicamen Biotech Reports Quarterly Financial Results for Period Ended September 30, 2025

Medicamen Biotech Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, showing net profit after tax of Rs. 304.22 lakhs for standalone operations. The biotech company's cash and bank balances increased significantly to Rs. 4,351.23 lakhs from Rs. 358.03 lakhs in the previous year, primarily driven by proceeds from share capital issuance of Rs. 84.82 lakhs and securities premium of Rs. 4,410.72 lakhs.

14 Nov 2025

earnings

Medicameq Ltd Approves Q1 FY26 Results and Appoints Three New Directors

Medicameq Ltd approved its unaudited financial results for the quarter ended June 30, 2025. The board appointed Mr. Ashwani Kumar Sharma as Executive Director for five years, changing his role from Non-Executive Director. Two new Non-Executive Independent Directors were also appointed: Mr. Sham Goel, a Chartered Accountant with over 30 years of finance experience, and Mr. Shaival Saurabh, who has over 30 years of branding and advertising experience. The company's 32nd AGM is scheduled for September 26, 2025, and the board proposed a final dividend of 10% or Re. 1 per equity share for FY 2024-25. The auditors provided unmodified opinions on the quarterly results.

12 Aug 2025

corporate action

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800